"title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","characteristics_ch1.4","characteristics_ch1.5","characteristics_ch1.6","characteristics_ch1.7","molecule_ch1","extract_protocol_ch1","extract_protocol_ch1.1","extract_protocol_ch1.2","taxid_ch1","data_processing","data_processing.1","data_processing.2","data_processing.3","data_processing.4","data_processing.5","data_processing.6","platform_id","contact_name","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","data_row_count","instrument_model","library_selection","library_source","library_strategy","relation","supplementary_file_1","ac_planned_schedule:ch1","description_of_planned_arm:ch1","ecog_ps_baseline:ch1","pathologic_complete_response:ch1","planned_arm_code:ch1","pretreatment_lymphnode_stage:ch1","residual_cancer_burden_class:ch1","smoking_history:ch1","Response"
"102001_RNAseq","GSM5010296","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260697","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","C","N1-2 (biopsy positive)","2","Current","NE"
"102003_RNAseq","GSM5010297","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260695","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Former","NE"
"102004_RNAseq","GSM5010298","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260694","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Former","E"
"104006_RNAseq","GSM5010299","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260692","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","B","N0 (clinically negative or biopsy negative)","0","Former","E"
"104007_RNAseq","GSM5010300","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260691","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","3","Never","NE"
"104008_RNAseq","GSM5010301","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260689","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"104009_RNAseq","GSM5010302","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260630","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Former","E"
"104010_RNAseq","GSM5010303","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260629","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","3","Never","NE"
"105002_RNAseq","GSM5010304","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260628","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","1","Never","NE"
"105003_RNAseq","GSM5010305","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260627","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"105004_RNAseq","GSM5010306","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260626","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"105005_RNAseq","GSM5010307","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260693","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"105006_RNAseq","GSM5010308","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260625","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"105007_RNAseq","GSM5010309","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260624","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"106004_RNAseq","GSM5010310","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260623","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"106006_RNAseq","GSM5010311","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260622","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","2","Never","NE"
"106007_RNAseq","GSM5010312","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260621","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Former","E"
"106008_RNAseq","GSM5010313","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260620","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"106009_RNAseq","GSM5010314","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260619","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Never","NE"
"106010_RNAseq","GSM5010315","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260618","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","2","Never","NE"
"106012_RNAseq","GSM5010316","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260617","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"106013_RNAseq","GSM5010317","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260616","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Current","NE"
"107003_RNAseq","GSM5010318","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260656","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"107007_RNAseq","GSM5010319","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260655","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Former","E"
"107008_RNAseq","GSM5010320","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260654","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Former","NE"
"107010_RNAseq","GSM5010321","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260653","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","1","Former","NE"
"107015_RNAseq","GSM5010322","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260652","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Former","E"
"107016_RNAseq","GSM5010323","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260651","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","2","Never","NE"
"107017_RNAseq","GSM5010324","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260650","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"107019_RNAseq","GSM5010325","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260649","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Former","E"
"109002_RNAseq","GSM5010326","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260648","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Former","NE"
"110008_RNAseq","GSM5010327","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260647","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"110010_RNAseq","GSM5010328","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260646","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Never","NE"
"110014_RNAseq","GSM5010329","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260644","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","2","Never","NE"
"110015_RNAseq","GSM5010330","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260643","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Current","E"
"110016_RNAseq","GSM5010331","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260642","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","1","Current","NE"
"110018_RNAseq","GSM5010332","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260570","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","NA","Former","NE"
"110019_RNAseq","GSM5010333","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260569","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Current","E"
"112004_RNAseq","GSM5010334","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260568","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","2","Never","NE"
"112006_RNAseq","GSM5010335","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260567","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"112007_RNAseq","GSM5010336","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260566","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","A","N0 (clinically negative or biopsy negative)","0","Former","E"
"113001_RNAseq","GSM5010337","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260645","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Former","E"
"114001_RNAseq","GSM5010338","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260565","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","NA","Never","NE"
"114003_RNAseq","GSM5010339","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260564","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","NA","Never","NE"
"114007_RNAseq","GSM5010340","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260563","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","NA","Never","E"
"114008_RNAseq","GSM5010341","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260562","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","NA","Never","NE"
"116001_RNAseq","GSM5010342","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260561","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","2","Current","NE"
"117003_RNAseq","GSM5010343","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260560","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Former","E"
"117005_RNAseq","GSM5010344","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260559","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","1","Never","NE"
"117007_RNAseq","GSM5010345","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260558","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Former","E"
"117009_RNAseq","GSM5010346","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260557","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","1","Never","NE"
"121002_RNAseq","GSM5010347","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260556","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","1","Never","NE"
"121003_RNAseq","GSM5010348","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260596","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Never","NE"
"121004_RNAseq","GSM5010349","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260595","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","1","Former","NE"
"121005_RNAseq","GSM5010350","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Unknown","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260594","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Unknown","E"
"123001_RNAseq","GSM5010351","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260593","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","3","Former","NE"
"123002_RNAseq","GSM5010352","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260592","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Current","NE"
"124003_RNAseq","GSM5010353","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260591","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","1","Never","NE"
"124004_RNAseq","GSM5010354","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260590","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Never","E"
"128001_RNAseq","GSM5010355","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260589","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","NA","Never","E"
"128002_RNAseq","GSM5010356","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260588","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N1-2 (biopsy positive)","NA","Never","E"
"129001_RNAseq","GSM5010357","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260587","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","NA","Never","NE"
"129002_RNAseq","GSM5010358","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260586","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","NA","Never","NE"
"129005_RNAseq","GSM5010359","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260585","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"129006_RNAseq","GSM5010360","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260583","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Never","NE"
"129008_RNAseq","GSM5010361","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260582","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","2","Never","NE"
"132001_RNAseq","GSM5010362","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260581","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N1-2 (biopsy positive)","0","Never","E"
"133001_RNAseq","GSM5010363","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260580","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","NA","Current","NE"
"135001_RNAseq","GSM5010364","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260579","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"136003_RNAseq","GSM5010365","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260615","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Current","E"
"136004_RNAseq","GSM5010366","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260614","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","3","Never","NE"
"139001_RNAseq","GSM5010367","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260584","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","2","Never","NE"
"139002_RNAseq","GSM5010368","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260613","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N1-2 (biopsy positive)","0","Never","E"
"144001_RNAseq","GSM5010369","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260612","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","1","Former","NE"
"147001_RNAseq","GSM5010370","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260611","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Current","NE"
"147002_RNAseq","GSM5010371","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260610","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Former","E"
"148001_RNAseq","GSM5010372","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260609","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"148002_RNAseq","GSM5010373","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260608","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Never","NE"
"149001_RNAseq","GSM5010374","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260607","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","1","Current","NE"
"149003_RNAseq","GSM5010375","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260606","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Former","E"
"150001_RNAseq","GSM5010376","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260605","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","NA","Never","NE"
"154002_RNAseq","GSM5010377","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260604","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N1-2 (biopsy positive)","0","Never","E"
"154003_RNAseq","GSM5010378","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Unknown","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260603","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Unknown","NE"
"156001_RNAseq","GSM5010379","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260602","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Never","NE"
"156002_RNAseq","GSM5010380","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260601","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"156003_RNAseq","GSM5010381","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260600","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Current","E"
"159001_RNAseq","GSM5010382","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260599","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","NA","Current","NE"
"159002_RNAseq","GSM5010383","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260598","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","NA","Never","E"
"159003_RNAseq","GSM5010384","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260597","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","NA","Never","NE"
"159004_RNAseq","GSM5010385","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260638","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","NA","Never","NE"
"161001_RNAseq","GSM5010386","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260637","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","NA","Never","NE"
"161002_RNAseq","GSM5010387","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260636","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Former","E"
"161003_RNAseq","GSM5010388","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260635","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","NA","Never","NE"
"164001_RNAseq","GSM5010389","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260634","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","2","Never","NE"
"164002_RNAseq","GSM5010390","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260633","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"164003_RNAseq","GSM5010391","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260632","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","2","Never","NE"
"164004_RNAseq","GSM5010392","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260631","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"164005_RNAseq","GSM5010393","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260515","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","1","Never","NE"
"165002_RNAseq","GSM5010394","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260514","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"190001_RNAseq","GSM5010395","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260555","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"190002_RNAseq","GSM5010396","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260554","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","NA","Never","NE"
"190003_RNAseq","GSM5010397","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260553","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"190004_RNAseq","GSM5010398","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260552","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Current","E"
"192001_RNAseq","GSM5010399","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260551","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","NA","Never","NE"
"193001_RNAseq","GSM5010400","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260550","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Former","E"
"193002_RNAseq","GSM5010401","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260549","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","2","Never","NE"
"193003_RNAseq","GSM5010402","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260548","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","NA","Never","NE"
"193004_RNAseq","GSM5010403","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260547","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"200004_RNAseq","GSM5010404","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260546","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"200006_RNAseq","GSM5010405","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260545","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"200009_RNAseq","GSM5010406","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260544","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Never","E"
"200010_RNAseq","GSM5010407","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260543","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","2","Current","NE"
"200012_RNAseq","GSM5010408","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260542","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"200013_RNAseq","GSM5010409","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260541","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","A","N1-2 (biopsy positive)","NA","Never","NE"
"200016_RNAseq","GSM5010410","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260540","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","NA","Never","NE"
"200018_RNAseq","GSM5010411","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260539","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"200021_RNAseq","GSM5010412","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260538","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","NA","Never","NE"
"201006_RNAseq","GSM5010413","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260537","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"201008_RNAseq","GSM5010414","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260536","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"201010_RNAseq","GSM5010415","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260535","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"201011_RNAseq","GSM5010416","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260578","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Never","E"
"201013_RNAseq","GSM5010417","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260577","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Never","NE"
"201014_RNAseq","GSM5010418","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260575","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"201015_RNAseq","GSM5010419","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260574","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Current","E"
"201016_RNAseq","GSM5010420","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260573","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Current","NE"
"201017_RNAseq","GSM5010421","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260572","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"202003_RNAseq","GSM5010422","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260571","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"202004_RNAseq","GSM5010423","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260011","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"202012_RNAseq","GSM5010424","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260009","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"203001_RNAseq","GSM5010425","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260007","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","NA","Former","NE"
"203006_RNAseq","GSM5010426","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260005","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"204002_RNAseq","GSM5010427","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260004","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Current","E"
"204003_RNAseq","GSM5010428","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260001","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Former","E"
"204004_RNAseq","GSM5010429","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260000","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","A","N0 (clinically negative or biopsy negative)","0","Former","E"
"204005_RNAseq","GSM5010430","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259999","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Never","NE"
"204006_RNAseq","GSM5010431","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259998","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","1","Former","NE"
"204007_RNAseq","GSM5010432","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259996","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","2","Current","NE"
"204008_RNAseq","GSM5010433","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259741","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"204010_RNAseq","GSM5010434","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259740","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","3","Never","NE"
"204012_RNAseq","GSM5010435","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259739","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Current","NE"
"204015_RNAseq","GSM5010436","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259738","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Never","E"
"210007_RNAseq","GSM5010437","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259737","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Former","E"
"210008_RNAseq","GSM5010438","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259734","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"210011_RNAseq","GSM5010439","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259733","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","A","N0 (clinically negative or biopsy negative)","1","Former","NE"
"211003_RNAseq","GSM5010440","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259732","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","B","N0 (clinically negative or biopsy negative)","0","Former","E"
"211004_RNAseq","GSM5010441","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259731","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Former","E"
"211005_RNAseq","GSM5010442","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259730","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","1","Never","NE"
"211006_RNAseq","GSM5010443","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259763","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","2","Former","NE"
"211007_RNAseq","GSM5010444","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259762","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"211009_RNAseq","GSM5010445","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259760","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","1","Current","NE"
"211010_RNAseq","GSM5010446","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259759","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","2","Never","NE"
"211011_RNAseq","GSM5010447","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259758","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","2","Current","NE"
"211012_RNAseq","GSM5010448","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259755","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","A","N1-2 (biopsy positive)","NA","Current","NE"
"212006_RNAseq","GSM5010449","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259754","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Never","NE"
"212007_RNAseq","GSM5010450","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259752","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Current","E"
"212008_RNAseq","GSM5010451","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259751","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Never","E"
"212009_RNAseq","GSM5010452","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259750","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"214006_RNAseq","GSM5010453","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259749","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","3","Never","NE"
"214007_RNAseq","GSM5010454","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259746","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Never","E"
"214009_RNAseq","GSM5010455","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259973","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","3","Never","NE"
"214010_RNAseq","GSM5010456","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259971","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","1","Never","NE"
"214011_RNAseq","GSM5010457","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259970","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N1-2 (biopsy positive)","0","Never","E"
"214012_RNAseq","GSM5010458","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259968","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","1","Former","NE"
"214014_RNAseq","GSM5010459","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259967","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","2","Never","NE"
"214015_RNAseq","GSM5010460","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259966","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Never","E"
"215005_RNAseq","GSM5010461","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259775","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Never","NE"
"215008_RNAseq","GSM5010462","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259772","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"216002_RNAseq","GSM5010463","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259769","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Former","E"
"216004_RNAseq","GSM5010464","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Unknown","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259768","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","3","Unknown","NE"
"217004_RNAseq","GSM5010465","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259767","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"217005_RNAseq","GSM5010466","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259765","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Former","E"
"217006_RNAseq","GSM5010467","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260014","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"217007_RNAseq","GSM5010468","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259989","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","1","Never","NE"
"217008_RNAseq","GSM5010469","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259985","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"217009_RNAseq","GSM5010470","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259981","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Never","E"
"217010_RNAseq","GSM5010471","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260074","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Former","E"
"217011_RNAseq","GSM5010472","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260073","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Never","NE"
"217012_RNAseq","GSM5010473","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260071","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"217013_RNAseq","GSM5010474","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260069","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","1","Never","NE"
"217014_RNAseq","GSM5010475","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260068","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Former","E"
"217017_RNAseq","GSM5010476","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260064","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","NA","Former","NE"
"219005_RNAseq","GSM5010477","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260063","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","NA","Never","E"
"219006_RNAseq","GSM5010478","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260061","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"219007_RNAseq","GSM5010479","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260058","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","1","Former","NE"
"220001_RNAseq","GSM5010480","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260054","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","A","N1-2 (biopsy positive)","NA","Former","NE"
"220002_RNAseq","GSM5010481","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260049","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","NA","Never","NE"
"220005_RNAseq","GSM5010482","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260048","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","NA","Never","E"
"220006_RNAseq","GSM5010483","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260750","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","NA","Never","E"
"221003_RNAseq","GSM5010484","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260746","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Never","NE"
"221004_RNAseq","GSM5010485","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260744","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Former","E"
"221005_RNAseq","GSM5010486","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260743","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"221006_RNAseq","GSM5010487","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260742","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","2","Never","NE"
"221007_RNAseq","GSM5010488","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260741","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Former","NE"
"221008_RNAseq","GSM5010489","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260774","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Never","E"
"230001_RNAseq","GSM5010490","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260773","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","2","Never","NE"
"232001_RNAseq","GSM5010491","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260772","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"250001_RNAseq","GSM5010492","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260771","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"260001_RNAseq","GSM5010493","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260770","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","1","Former","NE"
"270001_RNAseq","GSM5010494","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260769","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","A","N0 (clinically negative or biopsy negative)","NA","Never","NE"
"270002_RNAseq","GSM5010495","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260768","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","NA","Former","NE"
"300001_RNAseq","GSM5010496","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260767","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","2","Current","NE"
"300002_RNAseq","GSM5010497","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260766","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","1","Never","NE"
"300003_RNAseq","GSM5010498","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260765","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Former","NE"
"300004_RNAseq","GSM5010499","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260764","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"300005_RNAseq","GSM5010500","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260762","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","3","Current","NE"
"300006_RNAseq","GSM5010501","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260761","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"301001_RNAseq","GSM5010502","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260760","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"401001_RNAseq","GSM5010503","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260759","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","A","N0 (clinically negative or biopsy negative)","0","Current","E"
"402004_RNAseq","GSM5010504","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Unknown","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260757","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","NA","Unknown","NE"
"402005_RNAseq","GSM5010505","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Unknown","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260756","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","1","Unknown","NE"
"402006_RNAseq","GSM5010506","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Unknown","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260755","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","NA","Unknown","NE"
"403001_RNAseq","GSM5010507","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260798","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","1","Never","NE"
"403002_RNAseq","GSM5010508","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260797","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Former","NE"
"403003_RNAseq","GSM5010509","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259551","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"403006_RNAseq","GSM5010510","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259550","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Current","NE"
"403008_RNAseq","GSM5010511","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259549","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"404001_RNAseq","GSM5010512","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259548","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","NA","Never","E"
"408001_RNAseq","GSM5010513","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259547","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Never","E"
"408002_RNAseq","GSM5010514","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259601","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","1","Former","NE"
"408005_RNAseq","GSM5010515","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259553","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Never","E"
"408006_RNAseq","GSM5010516","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259552","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"408007_RNAseq","GSM5010517","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259546","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"408008_RNAseq","GSM5010518","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259545","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Former","NE"
"408009_RNAseq","GSM5010519","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259544","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","3","Never","NE"
"408010_RNAseq","GSM5010520","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259543","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","2","Never","NE"
"408011_RNAseq","GSM5010521","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259542","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","NA","Never","E"
"408012_RNAseq","GSM5010522","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259541","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","NA","Never","E"
"408013_RNAseq","GSM5010523","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259540","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"408014_RNAseq","GSM5010524","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259539","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"451003_RNAseq","GSM5010525","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259538","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","1","Current","NE"
"451004_RNAseq","GSM5010526","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259537","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","2","Never","NE"
"451006_RNAseq","GSM5010527","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Unknown","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259536","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","2","Unknown","NE"
"451007_RNAseq","GSM5010528","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259620","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","NA","Never","NE"
"453001_RNAseq","GSM5010529","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259619","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Former","E"
"500001_RNAseq","GSM5010530","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259618","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"500002_RNAseq","GSM5010531","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259617","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Never","E"
"500003_RNAseq","GSM5010532","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259616","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Current","E"
"500005_RNAseq","GSM5010533","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259615","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","A","N1-2 (biopsy positive)","NA","Never","NE"
"501003_RNAseq","GSM5010534","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259614","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Current","NE"
"501004_RNAseq","GSM5010535","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259613","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","NA","Never","E"
"501005_RNAseq","GSM5010536","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259612","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","NA","Current","NE"
"501006_RNAseq","GSM5010537","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259611","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","NA","Current","NE"
"502001_RNAseq","GSM5010538","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17259610","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"502002_RNAseq","GSM5010539","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Unknown","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260482","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Unknown","NE"
"502003_RNAseq","GSM5010540","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260481","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Current","E"
"502004_RNAseq","GSM5010541","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Unknown","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260480","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","2","Unknown","NE"
"507001_RNAseq","GSM5010542","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260479","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","NA","Current","E"
"507003_RNAseq","GSM5010543","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260478","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","NA","Current","NE"
"508001_RNAseq","GSM5010544","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260477","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"508002_RNAseq","GSM5010545","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260476","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"508003_RNAseq","GSM5010546","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Unknown","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260475","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Unknown","E"
"508004_RNAseq","GSM5010547","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260474","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"508005_RNAseq","GSM5010548","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260473","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"508006_RNAseq","GSM5010549","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260472","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Current","E"
"509001_RNAseq","GSM5010550","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260471","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"512001_RNAseq","GSM5010551","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260470","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","A","N0 (clinically negative or biopsy negative)","2","Current","NE"
"512002_RNAseq","GSM5010552","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260469","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","A","N0 (clinically negative or biopsy negative)","0","Current","E"
"512003_RNAseq","GSM5010553","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260468","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","A","N1-2 (biopsy positive)","0","Current","E"
"512004_RNAseq","GSM5010554","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260467","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"512005_RNAseq","GSM5010555","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260466","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","A","N1-2 (biopsy positive)","2","Current","NE"
"512006_RNAseq","GSM5010556","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Unknown","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260465","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","C","N1-2 (biopsy positive)","0","Unknown","E"
"512007_RNAseq","GSM5010557","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260464","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"512009_RNAseq","GSM5010558","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260513","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","A","N1-2 (biopsy positive)","1","Never","NE"
"512010_RNAseq","GSM5010559","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260512","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","C","N0 (clinically negative or biopsy negative)","2","Current","NE"
"514001_RNAseq","GSM5010560","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260511","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","NA","Never","E"
"514002_RNAseq","GSM5010561","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260510","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","NA","Current","E"
"514007_RNAseq","GSM5010562","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260509","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Never","NE"
"516001_RNAseq","GSM5010563","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260508","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Former","NE"
"555002_RNAseq","GSM5010564","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260507","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Never","NE"
"555003_RNAseq","GSM5010565","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260506","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Current","E"
"555004_RNAseq","GSM5010566","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260505","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Never","NE"
"555005_RNAseq","GSM5010567","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260504","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"555006_RNAseq","GSM5010568","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260803","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","NA","Never","NE"
"555007_RNAseq","GSM5010569","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260802","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"555008_RNAseq","GSM5010570","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260801","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","2","Never","NE"
"556002_RNAseq","GSM5010571","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260800","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","NA","Never","NE"
"556003_RNAseq","GSM5010572","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Unknown","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260799","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","NA","Unknown","NE"
"557001_RNAseq","GSM5010573","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260835","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","2","Current","NE"
"557002_RNAseq","GSM5010574","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260834","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","1","Former","NE"
"557004_RNAseq","GSM5010575","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260833","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Never","NE"
"558002_RNAseq","GSM5010576","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260832","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","NA","Current","E"
"560002_RNAseq","GSM5010577","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260831","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"560003_RNAseq","GSM5010578","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260830","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Current","E"
"560004_RNAseq","GSM5010579","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260829","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"564001_RNAseq","GSM5010580","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260828","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","NA","Never","NE"
"564002_RNAseq","GSM5010581","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260827","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Current","NE"
"566001_RNAseq","GSM5010582","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260826","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","3","Never","NE"
"567001_RNAseq","GSM5010583","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260825","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Former","NE"
"569001_RNAseq","GSM5010584","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260824","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Never","NE"
"573001_RNAseq","GSM5010585","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260823","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","3","Current","NE"
"573002_RNAseq","GSM5010586","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260822","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"573003_RNAseq","GSM5010587","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260821","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Current","E"
"573004_RNAseq","GSM5010588","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260820","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"574001_RNAseq","GSM5010589","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260819","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","2","Current","NE"
"574002_RNAseq","GSM5010590","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260818","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","1","Never","NE"
"574003_RNAseq","GSM5010591","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260817","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Former","E"
"574005_RNAseq","GSM5010592","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Unknown","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260816","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","1","Unknown","NE"
"575001_RNAseq","GSM5010593","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260850","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","A","N0 (clinically negative or biopsy negative)","0","Former","E"
"575002_RNAseq","GSM5010594","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260849","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Never","NE"
"581001_RNAseq","GSM5010595","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260848","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Former","E"
"581002_RNAseq","GSM5010596","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260847","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","1","Never","NE"
"581004_RNAseq","GSM5010597","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260846","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Never","NE"
"581005_RNAseq","GSM5010598","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260845","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","2","Never","NE"
"584001_RNAseq","GSM5010599","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260844","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"584002_RNAseq","GSM5010600","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260843","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"584003_RNAseq","GSM5010601","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260842","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Former","E"
"584004_RNAseq","GSM5010602","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260841","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"593001_RNAseq","GSM5010603","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260840","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Never","NE"
"593002_RNAseq","GSM5010604","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260839","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","2","Former","NE"
"651001_RNAseq","GSM5010605","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260838","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","1","Never","NE"
"651002_RNAseq","GSM5010606","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260837","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Current","E"
"652001_RNAseq","GSM5010607","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260836","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Former","NE"
"652003_RNAseq","GSM5010608","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260462","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","3","Never","NE"
"652004_RNAseq","GSM5010609","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Unknown","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260461","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Unknown","E"
"652008_RNAseq","GSM5010610","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260460","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","1","Never","NE"
"653001_RNAseq","GSM5010611","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260459","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Current","NE"
"653002_RNAseq","GSM5010612","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260458","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Former","NE"
"653005_RNAseq","GSM5010613","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260457","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Former","E"
"653006_RNAseq","GSM5010614","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260456","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","2","Never","NE"
"655001_RNAseq","GSM5010615","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260455","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"702001_RNAseq","GSM5010616","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260454","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"702002_RNAseq","GSM5010617","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260453","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","1","Current","NE"
"702003_RNAseq","GSM5010618","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260452","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Never","NE"
"702004_RNAseq","GSM5010619","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260451","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Current","E"
"702005_RNAseq","GSM5010620","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260450","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Current","E"
"702007_RNAseq","GSM5010621","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260449","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"702009_RNAseq","GSM5010622","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260448","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"702011_RNAseq","GSM5010623","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260447","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"702012_RNAseq","GSM5010624","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260446","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","2","Current","NE"
"704004_RNAseq","GSM5010625","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260445","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","NA","Never","NE"
"704005_RNAseq","GSM5010626","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260444","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","NA","Current","NE"
"706002_RNAseq","GSM5010627","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260443","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"706003_RNAseq","GSM5010628","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260492","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","NA","Current","NE"
"706005_RNAseq","GSM5010629","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260491","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Current","E"
"706006_RNAseq","GSM5010630","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260490","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Former","E"
"706007_RNAseq","GSM5010631","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260489","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"706008_RNAseq","GSM5010632","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260503","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Former","E"
"706012_RNAseq","GSM5010633","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260502","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","1","Never","NE"
"721001_RNAseq","GSM5010634","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260488","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","NA","Never","NE"
"721002_RNAseq","GSM5010635","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260487","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","NA","Former","E"
"721004_RNAseq","GSM5010636","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260486","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","NA","Former","E"
"740002_RNAseq","GSM5010637","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260485","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N1-2 (biopsy positive)","0","Never","E"
"740003_RNAseq","GSM5010638","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260484","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Never","NE"
"740005_RNAseq","GSM5010639","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260483","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"740006_RNAseq","GSM5010640","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260501","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","2","Never","NE"
"740008_RNAseq","GSM5010641","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260500","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Current","E"
"740009_RNAseq","GSM5010642","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260499","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Current","NE"
"744001_RNAseq","GSM5010643","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260498","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","C","N0 (clinically negative or biopsy negative)","2","Never","NE"
"744002_RNAseq","GSM5010644","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260497","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","3","Never","NE"
"744004_RNAseq","GSM5010645","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260496","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Current","NE"
"745002_RNAseq","GSM5010646","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260495","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Current","E"
"745003_RNAseq","GSM5010647","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260494","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"745005_RNAseq","GSM5010648","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260493","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","B","N0 (clinically negative or biopsy negative)","2","Never","NE"
"745006_RNAseq","GSM5010649","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260534","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","2","Former","NE"
"745007_RNAseq","GSM5010650","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260533","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","C","N0 (clinically negative or biopsy negative)","0","Current","E"
"745010_RNAseq","GSM5010651","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260532","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","B","N1-2 (biopsy positive)","2","Never","NE"
"745011_RNAseq","GSM5010652","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260531","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Current","E"
"747002_RNAseq","GSM5010653","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260530","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"747003_RNAseq","GSM5010654","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260529","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","B","N0 (clinically negative or biopsy negative)","1","Former","NE"
"747008_RNAseq","GSM5010655","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260528","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","NA","Never","NE"
"747011_RNAseq","GSM5010656","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260527","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","2","Former","NE"
"760002_RNAseq","GSM5010657","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260526","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","2","Never","NE"
"762002_RNAseq","GSM5010658","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260525","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"763001_RNAseq","GSM5010659","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260524","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","3","Never","NE"
"763003_RNAseq","GSM5010660","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260523","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"763004_RNAseq","GSM5010661","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260522","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Current","E"
"763005_RNAseq","GSM5010662","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260521","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Current","E"
"764002_RNAseq","GSM5010663","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260520","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","NA","Never","E"
"764003_RNAseq","GSM5010664","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260519","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","NA","Never","NE"
"766001_RNAseq","GSM5010665","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260518","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","2","Never","NE"
"767001_RNAseq","GSM5010666","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260517","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","NA","Former","NE"
"767003_RNAseq","GSM5010667","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260516","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","B","N1-2 (biopsy positive)","NA","Never","NE"
"770001_RNAseq","GSM5010668","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260235","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","2","Never","NE"
"770003_RNAseq","GSM5010669","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260234","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Never","E"
"770004_RNAseq","GSM5010670","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260233","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","2","Never","NE"
"770005_RNAseq","GSM5010671","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260232","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","2","Never","NE"
"771001_RNAseq","GSM5010672","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260231","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","1","Never","NE"
"820002_RNAseq","GSM5010673","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260230","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"820003_RNAseq","GSM5010674","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260229","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"820005_RNAseq","GSM5010675","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260228","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"820006_RNAseq","GSM5010676","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260353","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"820007_RNAseq","GSM5010677","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260351","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"820008_RNAseq","GSM5010678","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260349","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"820009_RNAseq","GSM5010679","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260348","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","2","Never","NE"
"820010_RNAseq","GSM5010680","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260346","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","1","Never","NE"
"820011_RNAseq","GSM5010681","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260345","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Never","E"
"820012_RNAseq","GSM5010682","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260343","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","2","Never","NE"
"820013_RNAseq","GSM5010683","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260341","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","2","Never","NE"
"821002_RNAseq","GSM5010684","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260340","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","3","Never","NE"
"821003_RNAseq","GSM5010685","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260338","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"821005_RNAseq","GSM5010686","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260336","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","2","Never","NE"
"821006_RNAseq","GSM5010687","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260335","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Never","NE"
"821009_RNAseq","GSM5010688","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260331","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","2","Never","NE"
"821010_RNAseq","GSM5010689","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260330","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","NA","Never","NE"
"821011_RNAseq","GSM5010690","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Unknown","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260328","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Unknown","E"
"821012_RNAseq","GSM5010691","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260327","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"821013_RNAseq","GSM5010692","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260325","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"821014_RNAseq","GSM5010693","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260405","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N1-2 (biopsy positive)","0","Never","E"
"821017_RNAseq","GSM5010694","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260404","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Never","NE"
"821018_RNAseq","GSM5010695","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260402","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"821019_RNAseq","GSM5010696","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Unknown","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260400","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","NA","Unknown","NE"
"821020_RNAseq","GSM5010697","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260399","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","3","Never","NE"
"821021_RNAseq","GSM5010698","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260168","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Never","NE"
"822001_RNAseq","GSM5010699","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260166","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"822002_RNAseq","GSM5010700","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260164","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"822003_RNAseq","GSM5010701","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260163","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","A","N0 (clinically negative or biopsy negative)","2","Never","NE"
"823001_RNAseq","GSM5010702","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260161","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Never","NE"
"823002_RNAseq","GSM5010703","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260159","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","2","Never","NE"
"823003_RNAseq","GSM5010704","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260158","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Never","NE"
"823004_RNAseq","GSM5010705","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260156","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"823006_RNAseq","GSM5010706","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260155","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","A","N0 (clinically negative or biopsy negative)","1","Never","NE"
"823007_RNAseq","GSM5010707","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260154","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"823008_RNAseq","GSM5010708","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260151","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N0 (clinically negative or biopsy negative)","0","Never","E"
"823009_RNAseq","GSM5010709","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260150","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"823010_RNAseq","GSM5010710","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260148","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"823011_RNAseq","GSM5010711","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260146","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"823012_RNAseq","GSM5010712","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260145","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","1","Never","NE"
"823013_RNAseq","GSM5010713","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260143","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"823014_RNAseq","GSM5010714","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260141","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","1","Never","NE"
"824003_RNAseq","GSM5010715","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260136","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","A","N0 (clinically negative or biopsy negative)","1","Never","NE"
"824004_RNAseq","GSM5010716","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260249","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","B","N0 (clinically negative or biopsy negative)","2","Never","NE"
"824005_RNAseq","GSM5010717","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260247","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","A","N1-2 (biopsy positive)","3","Never","NE"
"824006_RNAseq","GSM5010718","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260246","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","B","N1-2 (biopsy positive)","2","Never","NE"
"824007_RNAseq","GSM5010719","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260244","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","C","N1-2 (biopsy positive)","2","Never","NE"
"824008_RNAseq","GSM5010720","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260243","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","A","N1-2 (biopsy positive)","NA","Never","NE"
"824009_RNAseq","GSM5010721","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260242","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"824010_RNAseq","GSM5010722","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260241","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","B","N1-2 (biopsy positive)","2","Never","NE"
"825007_RNAseq","GSM5010723","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260240","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"825008_RNAseq","GSM5010724","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260239","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","A","N0 (clinically negative or biopsy negative)","2","Never","NE"
"825009_RNAseq","GSM5010725","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260238","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","2","Never","NE"
"825010_RNAseq","GSM5010726","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260237","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"825011_RNAseq","GSM5010727","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260236","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"825012_RNAseq","GSM5010728","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260414","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"825013_RNAseq","GSM5010729","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260413","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","B","N0 (clinically negative or biopsy negative)","2","Never","NE"
"825015_RNAseq","GSM5010730","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260412","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"826002_RNAseq","GSM5010731","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260411","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","2","Never","NE"
"827001_RNAseq","GSM5010732","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260410","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"827002_RNAseq","GSM5010733","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260409","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"827003_RNAseq","GSM5010734","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260408","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","NA","Never","NE"
"827005_RNAseq","GSM5010735","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260407","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","2","Never","NE"
"827006_RNAseq","GSM5010736","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260406","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N1-2 (biopsy positive)","0","Never","E"
"827008_RNAseq","GSM5010737","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260442","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","NA","Never","NE"
"827009_RNAseq","GSM5010738","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260441","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N1-2 (biopsy positive)","2","Never","NE"
"840001_RNAseq","GSM5010739","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260440","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","3","Never","NE"
"840002_RNAseq","GSM5010740","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260439","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Never","NE"
"840004_RNAseq","GSM5010741","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260438","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N1-2 (biopsy positive)","0","Never","E"
"840005_RNAseq","GSM5010742","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260437","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"841001_RNAseq","GSM5010743","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260436","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"841002_RNAseq","GSM5010744","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260435","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Former","NE"
"842001_RNAseq","GSM5010745","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260434","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"842002_RNAseq","GSM5010746","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260433","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","A","N0 (clinically negative or biopsy negative)","2","Never","NE"
"842003_RNAseq","GSM5010747","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260432","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","1","Never","NE"
"842004_RNAseq","GSM5010748","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260431","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"844004_RNAseq","GSM5010749","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260430","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","1","Former","NE"
"847001_RNAseq","GSM5010750","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 3","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260429","NONE","Every 2 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N1-2 (biopsy positive)","3","Never","NE"
"850001_RNAseq","GSM5010751","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260428","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Former","NE"
"850003_RNAseq","GSM5010752","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260427","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Never","E"
"850004_RNAseq","GSM5010753","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 2 weeks","smoking_history: Former","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260426","NONE","Every 2 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","0","Former","E"
"862001_RNAseq","GSM5010754","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260425","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","NA","Never","NE"
"862002_RNAseq","GSM5010755","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260424","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","NA","Never","NE"
"865009_RNAseq","GSM5010756","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260423","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","C","N0 (clinically negative or biopsy negative)","NA","Never","NE"
"867001_RNAseq","GSM5010757","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260463","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","NA","Never","NE"
"867002_RNAseq","GSM5010758","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260398","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","NA","Never","NE"
"868001_RNAseq","GSM5010759","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260397","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"868002_RNAseq","GSM5010760","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Current","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260396","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Current","NE"
"868007_RNAseq","GSM5010761","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260395","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"868008_RNAseq","GSM5010762","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260394","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","2","Never","NE"
"868009_RNAseq","GSM5010763","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260393","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","C","N1-2 (biopsy positive)","0","Never","E"
"868010_RNAseq","GSM5010764","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260392","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","C","N0 (clinically negative or biopsy negative)","2","Never","NE"
"868011_RNAseq","GSM5010765","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260391","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"869001_RNAseq","GSM5010766","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: C","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260390","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + PBO FOR CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","C","N0 (clinically negative or biopsy negative)","0","Never","E"
"869002_RNAseq","GSM5010767","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260389","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","B","N1-2 (biopsy positive)","0","Never","E"
"869003_RNAseq","GSM5010768","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260388","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","A","N0 (clinically negative or biopsy negative)","1","Never","NE"
"869004_RNAseq","GSM5010769","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: RD","residual_cancer_burden_class: 1","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260387","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","RD","A","N0 (clinically negative or biopsy negative)","1","Never","NE"
"869005_RNAseq","GSM5010770","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 1","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260422","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","1","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"880001_RNAseq","GSM5010771","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260421","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N1-2 (biopsy positive)","NA","Never","E"
"881001_RNAseq","GSM5010772","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260420","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Never","NE"
"881002_RNAseq","GSM5010773","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260419","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","A","N0 (clinically negative or biopsy negative)","0","Never","E"
"881003_RNAseq","GSM5010774","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N1-2 (biopsy positive)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260418","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N1-2 (biopsy positive)","2","Never","NE"
"883003_RNAseq","GSM5010775","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: pCR","residual_cancer_burden_class: 0","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260417","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","pCR","B","N0 (clinically negative or biopsy negative)","0","Never","E"
"883004_RNAseq","GSM5010776","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: B","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: NA","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260416","NONE","Every 3 weeks","PBO FOR VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","B","N0 (clinically negative or biopsy negative)","NA","Never","NE"
"883005_RNAseq","GSM5010777","Public on Jan 08 2021","Jan 08 2021","Jan 08 2021","SRA","1","Tumor biopsy","Homo sapiens","description_of_planned_arm: VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","planned_arm_code: A","pretreatment_lymphnode_stage: N0 (clinically negative or biopsy negative)","ac_planned_schedule: Every 3 weeks","smoking_history: Never","ecog_ps_baseline: 0","pathologic_complete_response: RD","residual_cancer_burden_class: 2","total RNA","Pre-treatment biopsies were collected in RNAlater and total RNA was extracted.","Total RNA underwent whole transcriptome RNA sequencing (RNAseq) using RiboZero Gold rRNA depletion","All samples were sequenced on an Illumina HiSeq 3000 with single-end 50bp reads","9606","Samples with >10 million unique reads were included for further analyses","RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b.","Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5.","Transcript counts were produced by Sailfish version 0.6.3.","Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models with RSeQC version 2.3.","Genome_build: Ensembl release 76","Supplementary_files_format_and_content: log2 normalized abundance data as a matrix table in a text file","GPL21290","Daniel,,Stover","Ohio State University Comprehensive Cancer Center","Biomedical Research Tower, Room 512, 460 W. 12th Avenue","Columbus","OH","43210","USA","0","Illumina HiSeq 3000","cDNA","transcriptomic","RNA-Seq","BioSample: https://www.ncbi.nlm.nih.gov/biosample/SAMN17260415","NONE","Every 3 weeks","VELIPARIB 50 MG BID + CARBOPLATIN AUC 6 + PACLITAXEL 80 MG/M^2","0","RD","A","N0 (clinically negative or biopsy negative)","2","Never","NE"
